Compound

GI50(m mol L-1 )

 

MCF-7

NCI-H460

SF-268

3a

30 ± 0.6

17.3 ± 1.4

22.3 ±1.5

3b

20 ± 0.4

24.3 ± 0.8

32 ± 0.8

5

70.6 ± 16.9

38.9 ± 10.8

50.8 ± 8.6

6

40.6 ± 12.2

32.6 ± 8.6

60.4 ± 14.8

7

0.4 ± 0.2

0.1 ± 0.08

0.9 ± 0.08

9

11.8 ± 0.6

14.5 ± 0.8

16.7 ± 1.6

12

72.7 ± 17.5

40.2 ± 12.8

50.0 ± 9.01

14

50.1 ± 0.7

23.2 ± 4.8

18.4 ± 1.8

17a

22.0 ± 0.2

30.6 ± 1.4

38.4 ± 0.6

17b

38.0 ± 1.8

44.0 ± 0.8

20.5 ± 1.1

19a

20.0 ± 0.6

22.0 ± 0.4

31.5 ± 8.0

19b

0.01 ± 0.006

0.04 ± 0.002

0.03 ± 0.005

21

70.9 ± 0.9

43.6 ± 1.8

56.8 ± 0.8

22

0.02 ± 0.009

0.06 ± 0.008

0.08 ± 0.001

Doxorubicin

0.04 ± 0.008

0.09 ± 0.008

0.09 ± 0.007

Results are given in concentrations that were able to cause 50 % of cell growth inhibition (GI50) after a continuous exposure of 48 h and show means SEM of three-independent experiments performed in duplicate.
Table 1: Effect of compounds 3a-21b on the growth of three human tumor cell lines.